Phase I, dose-escalating, randomized, comparator-controlled trial of the safety, tolerability, and immunogenicity of the co-administration of transmission-blocking vaccines (R0.6C-AlOH/ Matrix-M™ with Pfs230D1 EPA/Matrix-M™) and individual comparators (R0.6C-AlOH/ Matrix-M™; ProC6C-AlOH/ Matrix-M™ and Pfs230D1 EPA/Matrix-M™) against Plasmodium falciparum in adults in Mali: TBVax2

Start Date30 Jun 2022

Sponsor / Collaborator-

100 Clinical Results associated with Malaria vaccines(Biological Mimetics, Inc.)

100 Translational Medicine associated with Malaria vaccines(Biological Mimetics, Inc.)

100 Patents (Medical) associated with Malaria vaccines(Biological Mimetics, Inc.)

780

Literatures (Medical) associated with Malaria vaccines(Biological Mimetics, Inc.)

01 May 2025·The Lancet Infectious Diseases

RH5.1/Matrix-M: highlighting blood-stage malaria vaccines

Article

Author: Palacpac, Nirianne Marie Q ; Horii, Toshihiro

Blood-stage vaccines have not gained much support as a standalone, due in part to disappointing results from earlier clin. trials that underscored hurdles in achieving notable vaccine efficacy.The completion of the trial and analyses of trial outcomes are much awaited.These continuing efforts for next-generation malaria vaccines provide the necessary visibility to interest funders and industry in a disease that still primarily affects low-income and middle-income countries.

01 Apr 2025·Vaccine

Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development

Article

Author: McGugan, Glen ; Mo, Annie X ; Pesce, John T

In June 2024, the National Institute of Allergy and Infectious Diseases (NIAID) convened an expert consultation to guide strategic priorities for the research and development of next-generation whole Plasmodium falciparum sporozoite vaccine candidates. The focus was on genetically attenuated, late (liver stage) arresting replication competent (LARC) sporozoite vaccines. The meeting reviewed the World Health Organization (WHO) Preferred Product Characteristics (PPCs) for future malaria vaccines and drew lessons from previous malaria vaccine R&D and implementation efforts. Key discussions centered on critical features related to the Target Product Profiles (TPP) of LARC vaccines for various specified indications and relevant development strategies. The consultation identified knowledge gaps and suggested priorities and opportunities for future research and product development for LARC malaria sporozoite vaccines.

01 Apr 2025·Trends in Parasitology

Having your cake and eating it too – a new target for sporozoite-neutralising mAbs

Article

Author: Kaczmarski, Joe A ; Jackson, Colin J ; Cockburn, Ian A

Current malaria vaccines provide suboptimal, waning protection. Dacon et al. identify a protective post-translationally modified epitope on Plasmodium sporozoites that is absent from current vaccines. This discovery deepens our understanding of Plasmodium biology and may inform the development of improved vaccines and complementary prophylactic monoclonal antibodies.

100 Deals associated with Malaria vaccines(Biological Mimetics, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria	Discovery	United States	Biological Mimetics, Inc.	01 Jul 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Malaria vaccines(Biological Mimetics, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation